WELCOME TO MY BLOG ::

Selamat Datang Sahabat. Semoga kita menjadi saudara sejati, ketika KLIK anda mengantar masuk space ini semoga bukan ruang hampa yang menjenuhkan. Sangat tersanjung anda berkenaan membaca sejenak apapun yang tersaji disini. Sejurus lalu, meninggalkan komentar, kritik atau pesan bijak buat penghuni blog. Ekspresi anda dalam bentuk tulisan adalah ungkapan abstrak banyak keinginan yang ingin kita gapai. So, berekspresilah dengan tulus dan semangat. Mari kita pupuk semangat dan cita-cita tinggi.
OK

Minggu, 13 Desember 2009

New The Mechanisms Of Gene Regulation


Muhammad Fahri*
Mahasiswa Pasca Biotek Perikanan UB malang

New Research Into The Mechanisms Of Gene Regulation
Source: Penn State


A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth. Working with collaborators including Drs. Mitchell Weiss and Gerd Blobel at Children's Hospital of Philadelphia, they focused specifically on the complex process of producing red blood cells (erythrocytes). These cells contain large amounts of hemoglobin, a molecule essential for transporting oxygen throughout the body. Abnormalities in hemoglobin figure in many serious diseases, such as sickle-cell disease, and abnormalities in producing blood cells can lead to leukemias. The work will be published in the December 2009 issue of the journal Genome Research.

As erythroid cells mature into red blood cells, the transcription factor, GATA-1, turns the genes responsible for making different proteins on and off. Hardison's team worked with a special strain of mouse erythroid cells that lack the gene gata-1. These cells could not mature into red blood cells unless the researchers added the protein GATA-1 experimentally. This procedure allows the investigators to monitor how the genes respond to GATA-1.

GATA-1 binds to special sites on the cell's DNA. The first step of the project was to locate the genes that are affected by GATA-1, so the researchers conducted a genome-wide search after adding GATA-1 to the cells. Using microarrays developed by newer methods of manufacturing which allow for a much higher density of probes, the team examined 19,000 mouse genes using 45,000 probe sets, many more than previous researchers had been able to study.

They found that adding GATA-1 affected 2,616 genes significantly, which was defined as showing at least a twofold change in the amount of the gene's product. Substantially more genes (1,568) were turned down or off by GATA-1 than were turned on (1,048) by GATA-1. The rest showed little or no response to the addition of GATA-1.

Could the differences in gene response and expression be explained by the spatial patterning of GATA-1 binding? The team used two independent methods of mapping where the GATA-1 binding sites lay on the DNA, and how far those binding sites were from the responsive genes. The two methods yielded strikingly similar information. In all, they found 15,360 DNA segments occupied by GATA-1.

Genes responsive to GATA-1 tend to occur in clusters on the DNA, with each cluster being separated from the next by long regions without any responsive genes.

"We think each cluster of responsive genes may represent a regulatory domain," says Hardison. "This work also highlights the importance of local regulation by transcription factors."

One of the fascinating discoveries of this research is how the genes that are enhanced by GATA-1 differ from those that are repressed. Nearly all responsive genes (more than 88%) lie within 100 kilobase pairs (kb) of a GATA-1 site and more than 60% of those that are up-regulated are less than 5 kb away from the closest GATA-1 site. In contrast, 60% of repressed genes are up to 33 kb away from the closest DNA sites occupied by GATA-1. Enhanced genes also have more nearby GATA-1 sites than repressed genes do.

The team also found evidence that the specific motif on the DNA sites to which the GATA-1 binds when it enhances genes is strongly conserved evolutionarily, while the binding motifs for repressed genes are not so strongly conserved across different species. This suggests that the selective pressure to increase gene expression is stronger than that to decrease gene expression.

Another issue is whether or not GATA-1 forms a complex with TAL1 (T-cell acute lymphocytic leukemia protein 1) at the binding sites. Almost all (at least 83%) of the activated genes have one or more complexes of GATA-1 and TAL1 nearby. A substantial fraction (38%) of the repressed genes lack or have decreased amounts of TAL1 after GATA-1 is added. Thus for many genes, the presence of TAL1 at the GATA-1 binding sites distinguishes activation from repression. However, another class of repressed genes, comprising 62% of the total, have complexes of GATA-1 and TAL1 in their vicinity.

"It is not a simple relationship," explains Hardison. "Genes that are activated almost invariably have complexes of GATA-1 and TAL1 at the binding sites, and genes lacking TAL1 at the GATA1-binding sites are almost always down-regulated. This suggests a model in which the GATA-1/TAL1 complex is involved in gene activation. However, we also see a large number of repressed genes with both proteins at the binding sites. These data indicate that there must be at least two mechanisms for repressing genes in these red blood cells, and only one of those mechanisms involves a loss of TAL1," concludes Hardison.

Another factor involved in regulating the expression of genes responsive to GATA-1 is the modification of histone H3, a protein that coils and compresses DNA inside the nucleus. Overall, Hardison's team found that histone modification is common in the large regions of the DNA that contain the GATA-1 responsive genes and the GATA-1 binding sites, but histone modification does not occur in the adjacent "dead zones" that lack genes responsive to GATA-1.

One particular histone modification, the trimethylation of amino acid lysine at position 27 of histone H3 -- or H3K27me3 -- is well-known to be associated with repression of some genes. By analyzing the location and amount of H3K27me3 around GATA1-responsive genes, the team gained new insights into how this modification influences the expression of genes. As expected, genes enhanced by GATA-1 have very little H3K27me3. However, the two classes of repressed genes differ in the level of H3K27me3. Like enhanced genes, the repressed genes that retain TAL1 after the addition of GATA-1 have low levels of H3K27me3. Those genes that lose some or all of their TAL1 after adding GATA-1 have relatively high levels of H3K27me3.

One class of down-regulated genes, perhaps the one with low TAL1 and increased H3K27me3, may be directly repressed by GATA-1. Possibly GATA-1 recruits other proteins that help reduce the level of expression. This repressed state appears to be indicated by the presence of H3K27me3.

In addition, the team hypothesizes that there is another, indirect mechanism for repressing genes. They suggest that the capacity for a cell to transcribe genes and manufacture their products is limited. In effect, if the cell has a series of transcription factories -- each of which has particular favored "customers" (genes) -- then placing a big order for one set of customers (the genes promoted by GATA-1) will indirectly cause the gene products for other customers (those not being promoted by GATA-1) to be diminished. This scenario implies that all the GATA-1 responsive genes are served by a limited number of local transcription factories with limited capacities.

"Though we developed this hypothesis about gene regulation by studying erythrocytes," comments Hardison, "it could obviously apply to the more general function of many different types of gene regulation. Since almost every disease is related in some way to gene expression, this could provide a powerful new model for thinking about many different diseases and their treatment.

"For example," Hardison continues, "sickle-cell disease is a devastating illness affecting more than 70,000 Americans1. It is caused by mutations in hemoglobin genes. All adults still produce some amount of fetal hemoglobin, and that amount differs among individuals. Some sickle-cell patients produce relatively high levels of it, and these patients have much milder symptoms. If we could learn how to repress the genes that produce the defective hemoglobin and promote those that produce the fetal hemoglobin, we may be able to develop an important new therapy to combat this disease."

Other collaborators in the research are graduate students and research associates at Penn State (Yong Cheng, Weishing Wu, Swathi Ashok Kumar, David C. King, Kuan-Bei Chen, Ying Zhang, Daniela Drautz, Belinda Giardine), faculty at Penn State (Stephan A. Schuster, professor of biochemistry and molecular biology; Webb Miller, professor of biology and computer science and engineering; Francesca Chiaromonte, associate professor of statistics and health evaluation sciences; and Yu Zhang, assistant professor of statistics), and students and post-doctoral fellows at Children's Hospital of Philadelphia (Duonan Yu, Wulan Deng, Tamara Tripic).

This research was supported by funding from the National Institutes of Health, the Gordon and Betty Moore Foundation, and the Leukemia and Lymphoma Society.

http://www.cdc.gov/Features/SickleCell/ accessed Nov. 8, 2009
http://news.biocompare.com/News/NewsStory/300296/NewsStory.html

CONTACTS
Ross Hardison: (+1)814-863-0113, rch8@psu.edu
Barbara Kennedy (PIO): 814-863-4682, science@psu.edu

Researchers Identify Role of Gene in Tumor Development, Growth and Progression
Source: Virginia Commonwealth University


Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.

According to Paul B. Fisher, M.Ph., Ph.D., professor and chair of the Department of Human and Molecular Genetics, director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, and program leader of Cancer Molecular Genetics at the Massey Cancer Center, the team has shown that astrocyte elevated gene-1, AEG-1, a cancer promoting gene, is involved in both oncogenic transformation, which is the conversion of a normal cell to a cancer cell, and angiogenesis, which is the formation of new blood cells. Oncogenic transformation and angiogenesis are critical for tumor development, growth and progression to metastasis.

In the study published online the week of Nov. 16 in the Early Edition of the journal Proceedings of the National Academy of Sciences, researchers employing a series of molecular studies reported that the elevated expression of AEG-1 is involved with turning normal cells into cancer cells.

According to Fisher, when AEG-1 was expressed in normal immortal rat embryo fibroblast cells it converted these cells into transformed cells that induced rapidly growing aggressive cancers when injected into animals. AEG-1 expressing cells displayed enhanced expression of genes regulating blood vessel formation, thereby contributing to tumorigenicity. The team has further defined the pathways in target cells that are activated by AEG-1 and mediate its oncogenic and angiogenic inducing properties.

“Our goal is to understand the functions of a novel gene AEG-1 that plays an essential role in tumor progression, with potential to develop effective therapeutic approaches for multiple cancers through targeted inhibition of this novel molecule or its downstream regulated processes,” said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.

“We believe it will pave the way for ameliorating the sufferings of scores of cancer patients by uncovering new and effective avenues for treatment,” he said.

To expand the work on AEG-1, the VCU Department of Human and Molecular Genetics, Institute of Molecular Medicine and Massey Cancer Center recently received a National Cancer Institute grant totaling $1.6 million to study the AEG-1 gene in the context of malignant brain tumors such as glioblastoma multiforme, or GBM. According to Fisher, who is the primary investigator for the study, the work will extend the understanding of this gene and how it may serve as an oncogenic, or transforming gene.

“Cancer development and progression are multi-factor and multi-step processes that occur in a temporal manner. As mentioned above AEG-1 clearly has multiple roles in various steps of tumor progression, including tumor cell growth, insensitivity to growth-inhibitory signals, including chemotherapeutic agents, invasion, angiogenesis and metastasis,” explained Fisher.
“In addition, AEG-1 has been known to have oncogenic roles in various cancers including glioma (CNS tumor), neuroblastoma, liver cancer, breast cancer, prostate cancer, lung cancer, and esophageal squamous cell carcinoma. These important correlations make this gene an intriguing molecule to study with potential to serve as a direct target for cancer therapy,” he said.

The gene was discovered in 2002 in Fisher’s laboratory while he was at the Columbia University College of Physicians and Surgeons in New York.

Fisher worked with a team that included VCU School of Medicine researchers Zao-zhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; Hyun Yong Jeon, M.S., research assistant with the VCU Department of Human and Molecular Genetics; Luni Emdad, M.D., Ph.D., with the Mount Sinai School of Medicine in New York; and Habib Boukerche, Ph.D., a senior scientist with the University Lyon 1 in France.

EDITOR’S NOTE: A copy of the study is available for reporters by email request from pnasnews@nas.edu.

About VCU and the VCU Medical Center:

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 205 certificate and degree programs in the arts, sciences and humanities. Sixty-five of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.

About the VCU Massey Cancer Center:

The VCU Massey CancerCenter is one of 63 National Cancer Institute-designated institutions that leads and shapes America’s cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Treating all kinds of cancers, its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and, ultimately, to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY


Paradoxical Protein Might Prevent Cancer
Source: Karolinska Institutet


One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells. By focusing on the differences, researchers at Karolinska Institutet have found a new way of tackling colon cancer. The study is presented in the prestigious journal Cell

Molecular signal pathways that stimulate the division of stem cells are generally the same as those active in tumour growth. This limits the possibility of treating cancer as the drugs that kill cancer cells also often adversely affect the body's healthy cells, particularly stem cells. A new study from Karolinska Institutet, conducted in collaboration with an international team of scientists led by Professor Jonas Frisén, is now focusing on an exception that can make it possible to treat a form of colon cancer.

The results concern a group of signal proteins called EphB receptors. These proteins stimulate the division of stem cells in the intestine and can contribute to the formation of adenoma (polyps), which are known to carry a risk of cancer. Paradoxically, these same proteins also prevent the adenoma from growing unchecked and becoming cancerous.

The new results show that EphB controls two separate signal pathways, one of which stimulates cell division and the other that curbs the cells' ability to become cancerous. Using this knowledge, the scientists have identified a drug substance called imatinib, which can inhibit the first signal pathway without affecting the other, protective, pathway.
"Imatinib or a similar substance could possibly be used for preventing the development of cancer in people who are in the risk zone for colon cancer instead of intestinal resection," says Maria Genander, one of the researchers involved in the study.

Imatinib has so far proved to inhibit cell division in intestinal tumour cells in vitro and in mice. The substance is a component of the drug Glivec, which is used, amongst other things, in the treatment of certain forms of leukaemia. Whether it can also be used against adenoma and colon cancer in humans remains to be seen. The company that manufactures the drug did not fund the study.

2 komentar:

Wisata Riau | Pekanbaru Riau mengatakan...

mampir Mas....
cuma bisa bisa manggut-manggut nih baca postnya:D
salam kenal.. dari Pekanbaru ..

Thailand aik aik mengatakan...

iya pak wisata riau. belum ditranslate deh. jadi sabar deh nunggu versi melayu neh. thanks telah berwisata di ruang blog ini. salam kenal.

Posting Komentar

Komentar Anda :

SAHABAT MAYA :

SEARCH LINK :

Label List

VISIT TOROWAMBA BEAUTY BEACH

VISIT TOROWAMBA BEAUTY BEACH
torowamba as one of tourism asset in sape bima

NEW MOTIVATION :

SUNGGUH SANGAT MEMALUKAN JIKA KAPAL BESAR KITA BERBALIK HALUAN KEBELAKANG HANYA UNTUK MENGURUS SAMPAN KECIL MASALAH. AYO !!! MAJU TERUS BRO !
Template by KangNoval & Abdul Munir | blog Blogger Templates